摘要:
A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.
摘要:
ADP-ribosylating toxins from Neisseria meningitidis, Streptomyces coelicolor, Mycoplasma pneumoniae, Salmonella typhimurium Salmonella paratyphi, and Streptococcus pyogenes are disclosed, together with mutant toxins and uses therefor. There is only a low level of sequence identity between these toxins and toxins such as cholera toxin and E. coli heat labile toxin.
摘要:
This invention provides polynucleotides encoding Helicobacter pylori cytotoxin associated immunodominant antigen. The polynucleotides can be used as probes to identify the presence of complementary target nucleotide sequences. The invention also provides kits and vectors containing the polynucleotides of the invention.
摘要:
Compositions comprising a first biological molecule from a Neisseria bacterium and a second biological molecule from a Neisseria bacterium. The term “biological molecule” includes proteins and nucleic acids. Preferred Neisseria species are N.meningitidis and N.gonorrhoeae.
摘要:
An immunogenic detoxified protein comprising the amino acid sequence of subunit A of a cholera toxin (CT-A) or a fragment thereof or the amino acid sequence of subunit A of an Escherichia coli heat labile toxin (LT-A) or a fragment thereof wherein the amino acids at, or in positions corresponding to Ser-63 and Arg-192 are replaced with another amino acid. The immunogenic detoxified protein is useful as vaccine for Vibrio cholerae or an enterotoxigenic strain of Escherichia coli and is produced by recombinant DNA means by site-directed mutagenesis.
摘要:
The present invention provides conjugate compounds comprising at least one heat shock protein or portion thereof including at least one immunostimulatory domain and at least one capsular oligosaccharide or polysaccharide of a pathogenic bacteria. The compound comprises oligosaccharides of the Meningococci C (MenC) group and a heat shock protein selected from M. bovis BCG GroE1-type 65 kDa hsp (hspR65), recombinant M. tuberculosis DnaK-type 70 kDa hsp (hspR70) and a heat shock protein from H. pylori. The invention also provides processes for producing conjugate compounds, pharmaceutical compositions comprising conjugate compounds, therapeutic compositions comprising conjugate compounds, and methods of inducing an immune response.
摘要:
A nasal dosage composition for nasal delivery comprising (A) a therapeutic agent; and (B) zonula occludens toxin, as well as a method for the use of the same.
摘要:
Method for the culture of microorganisms of the genera Helicobacter, Campylobacter and Arcobacter, wherein culture media are employed, which comprise, in place of blood or its derivative, cyclodextrins, methylcellulose or mixtures thereof.
摘要:
Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state.
摘要:
The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.